Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHF 1535 MDI versus Seretide Diskus in partially reversible COPD
2005-005857-23Phase 3Completed
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Oct 2006
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of beclomethasone dipropionate, formoterol, salmeterol and fluticasone propionate in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Chiesi Farmaceutici S.p.A. Primary endpoint: Endurance time. Started Oct 2006; status: completed.
02
Drugs
beclomethasone dipropionateformoterolsalmeterolfluticasone propionate
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2005-005857-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005857-23.